Home  »  Finance   »  What Are Structure Therapeutics Inc ADR’s Sh...

What Are Structure Therapeutics Inc ADR’s Short-Term Prospects?

Structure Therapeutics Inc ADR (NASDAQ:GPCR) price closed higher on Friday, November 17, jumping 12.14% above its previous close.

A look at the daily price movement shows that the last close reads $47.95, with intraday deals fluctuated between $46.72 and $53.96. Taking into account the 52-week price action we note that the stock hit a 52-week high of $75.02 and 52-week low of $20.80. The stock subtracted -19.70% on its value in the past month.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


Structure Therapeutics Inc ADR, which has a market valuation of $1.92 billion. Analysts tracking GPCR have forecast the quarterly EPS to shrink by -0.33 per share this quarter, while the same analysts predict the annual EPS to hit -$1.35 for the year 2023 and up to -$1.58 for 2024. In this case, analysts estimate an annual EPS growth of 75.50% for the year and -17.00% for the next year.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 6 analysts have assigned GPCR a recommendation rating as follows: 0 rate it as a Hold; 6 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Structure Therapeutics Inc ADR (GPCR) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that GPCR’s price is at present -16.95% off the SMA20 and -0.29% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 41.71, with weekly volatility standing at 11.58%. The indicator jumps to 8.09% when calculated based on the past 30 days. Structure Therapeutics Inc ADR (NASDAQ:GPCR)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 4.92. Considering analysts have assigned the stock a price target range of $79.00-$97.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $89.17. Based on this estimate, we see that current price is roughly -46.92% off the estimated low and -80.4% off the forecast high. Investors will no doubt be excited to see the share price fall to $91.50, which is the median consensus price, and at that level GPCR would be -70.17% from current price.

An analysis of the Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock in terms of its daily trading volume indicates that the 3-month average is 909.52K. However, this figure increases on the past 10-day timeline to an average of 1.04 million.

Current records show that the company has 36.59M in outstanding shares. The insiders’ percentage holdings are 5.10% of outstanding shares while the percentage share held by institutions stands at 81.49%. The stats also highlight that short interest as of Oct 30, 2023, stood at 2.74 million shares, which puts the short ratio at the time at 2.8. From this we can glean that short interest is 6.20% of company’s current outstanding shares. Notably, we see that shares short in October fall slightly given the previous month’s figure stood at 2.85 million. But the 106.81% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.